Cargando…

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States

A fixed‐dose combination (FDC) product of a selective sodium‐glucose cotransporter 2 inhibitor ertugliflozin and immediate‐release metformin is approved for type 2 diabetes mellitus in the United States, European Union countries, Canada, and other countries. Two studies were conducted to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dawra, Vikas Kumar, Pelletier, Kathleen, Matschke, Kyle, Shi, Haihong, Hickman, Anne, Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246554/ https://www.ncbi.nlm.nih.gov/pubmed/33135865 http://dx.doi.org/10.1002/cpdd.884

Ejemplares similares

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components
por: Fediuk, Daryl J., et al.
Publicado: (2019)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2018)

Relative bioavailability of ertugliflozin tablets containing the amorphous form versus tablets containing the cocrystal form
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2022)

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects
por: Li, Yinhua, et al.
Publicado: (2019)

Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin
por: Choi, Hyang-Ki, et al.
Publicado: (2015)

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial
por: Cosentino, Francesco, et al.
Publicado: (2022)

Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure
por: Marshall, Jean‐Claude, et al.
Publicado: (2021)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
por: Hollander, Priscilla, et al.
Publicado: (2017)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2023)

Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
por: Duckworth, Wiliam
Publicado: (2003)

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
por: Budoff, Matthew J., et al.
Publicado: (2021)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
por: Raje, Sangeeta, et al.
Publicado: (2018)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Ertugliflozin for type 2 diabetes [Correction]
Publicado: (2019)

Role of Ertugliflozin in the Management of Diabetes Mellitus
por: Totade, Manisha, et al.
Publicado: (2022)

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
por: Gallo, Silvina, et al.
Publicado: (2019)

Ertugliflozin in the treatment of type 2 diabetes mellitus
por: Marrs, Joel C, et al.
Publicado: (2020)

Bioequivalence Comparison of Two Formulations of Fixed-Dose Combination Glimepiride/Metformin (2/500 mg)Tablets in Healthy Volunteers
por: Jung, Sang-hoon, et al.
Publicado: (2014)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Fed and fasted bioequivalence assessment of two formulations of extended-release fixed-dose combination dapagliflozin/metformin (10/1,000 mg) tablets in healthy subjects
por: Lee, Hae Won, et al.
Publicado: (2023)

Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid
por: Callegari, Ernesto, et al.
Publicado: (2020)

Assessment of quality control parameters and in vitro bioequivalence/interchangeability of multisourced marketed metformin hydrochloride tablets
por: Younes, Husam, et al.
Publicado: (2017)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
por: Ghim, Jong-Lyul, et al.
Publicado: (2019)

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
por: Liu, Jie, et al.
Publicado: (2020)

Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
por: Liu, Hongyan, et al.
Publicado: (2021)

Effects of food on pharmacokinetics and safety of metformin hydrochloride tablets: A meta-analysis of pharmacokinetic, bioavailability, or bioequivalence studies
por: Sun, Ming-Li, et al.
Publicado: (2023)

Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
por: Cho, Yong-Soon, et al.
Publicado: (2018)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
por: Heymsfield, Steven B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ecegmidu5jtge9ugb6tu7su7v1